Adaptimmune Annual report pursuant to Section 13 and 15(d)

Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details)

Revenue - Collaboration Agreement - The Genentech Collaboration and License Agreement (Details) $ in Thousands		3 Months Ended	12 Months Ended
	Sep. 03, 2021 USD ($) item	Dec. 31, 2021 USD ($)	Dec. 31, 2022 USD ($)
Revenue
Number of additional terms \| item	2
Collaboration target basis days	180 days
Number of days without HSR clearance after effective date before termination	180 days
Strategic Collaboration and License Agreement
Revenue
Number of types of therapies to be co-developed \| item	2
Initial period of collaborated research	8 years
Number of additional terms \| item	2
Number of additional years	2 years
Number of years additional payments are due	5 years
Upfront payment received		$ 150,000
Amount of additional payments receivable under the research program	$ 150,000
Total Number off the Shelf Collaboration Targets \| item	5
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements			$ 283,206
Amount of transaction price of the agreement at inception			313,600
Collaboration Agreement Research Service and Rights, Upfront Payment Earned			150,000
Collaboration Agreement Research Service and Rights, Additional Payment Earned			150,000
Collaboration Agreement Research Service and Rights, Other Consideration			13,600
Strategic Collaboration and License Agreement \| Material Right to Designate the Additional Off the Shelf Collaboration Target
Revenue
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements			12,766
Strategic Collaboration and License Agreement \| Research Service Rights Granted for Initial Off the Shelf Collaboration Targets
Revenue
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements			174,125
Strategic Collaboration and License Agreement \| Research Service Rights Granted for Personalized Therapies
Revenue
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements			90,169
Strategic Collaboration and License Agreement \| Material Right for First Option Extend the Research Term
Revenue
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements			4,917
Strategic Collaboration and License Agreement \| Material Right for Second Option Extend the Research Term
Revenue
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements			$ 1,229
Development Milestone \| Strategic Collaboration and License Agreement \| Maximum
Revenue
Milestone payments	$ 200,000
Development Milestone - Off The Shelf Member T-cell Therapies \| Strategic Collaboration and License Agreement \| Maximum
Revenue
Milestone payments	100,000
Research Milestone \| Strategic Collaboration and License Agreement \| Maximum
Revenue
Milestone payments	$ 50,000
Commercialisation Milestone \| Strategic Collaboration and License Agreement
Revenue
Total Number off the Shelf Collaboration Targets \| item	5
Commercialisation Milestone \| Strategic Collaboration and License Agreement \| Maximum
Revenue
Milestone payments	$ 1,100,000
Sales Milestone \| Strategic Collaboration and License Agreement
Revenue
Number of co-development targets \| item	5
Sales Milestone \| Strategic Collaboration and License Agreement \| Maximum
Revenue
Milestone payments	$ 1,500,000
Regulatory, Sales, And Royalties Milestones \| Strategic Collaboration and License Agreement
Revenue
Percentage of profit (loss) sharing ratio	50.00%
Regulatory, Sales, And Royalties Milestones \| Strategic Collaboration and License Agreement \| Maximum
Revenue
Milestone payments	$ 800,000